A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

SELUTION SLR™ SUCCESS PTA Study : 1st Patient Is Enrolled

February 8, 2021

MedAlliance announced the enrolment of the first patient in SUCCESS PTA, its large post-market study with the drug-eluting balloon SELUTION SLR™ for the treatment of patients with peripheral artery disease (PAD).

SELUTION SLR is a novel sirolimus-eluting balloon that provides a controlled sustained release of the drug, similar to that of a drug-eluting stent (DES).

The objective of the study is to collect ‘real-world’ safety, efficacy, health economics, and patient-reported quality-of-life data in over 700 patients with PAD treated with SELUTION SLR. It is a single-arm all-comers study including all lower limb indications (SFA; BTK; Foot) and will cover at least 50 sites in Europe, Asia, and South America. Patients will be followed-up at 30 days; six months; then every year out to five years.

The primary endpoint of the study is Clinically Driven Target Lesion Revascularization (CD-TLR) at 12 months. Secondary endpoints include device success and procedure success; Major Adverse Limb Events (MALE); and Target Limb Revascularization (TLR).

“Given the impressive performance of this novel device in earlier studies, we are very excited to see how SELUTION SLR will perform in a larger group of patients in a real world setting”, commented the study’s Principal Investigator Michael Lichtenberg, Arnsberg, Germany.

“SUCCESS PTA is part of the SUCCESS post-market study family, designed to show patient benefits in real-world use of our technology”, added Chairman and CEO Jeffrey B. Jump. “This is the largest study we have ever undertaken with SELUTION SLR, involving the most diverse group of patients. We are confident that the results will confirm the safety, efficacy and cost-effectiveness of our sirolimus-eluting balloon.”

In February 2020 MedAlliance received CE Mark approval for SELUTION SLR in the treatment of PAD. This award was supported by results from the First-in-Human study.

Data from the SUCCESS PTA study will be part of the clinical evidence supporting CE Mark renewal in 2023/2024 under the new European Medical Device Directive (MDR).

SELUTION SLR has also received US Food and Drug Administration (FDA) Breakthrough Device Designation Status for peripheral below-the-knee lesions as well as for the treatment of AV-Fistula.

SELUTION SLR’s technology involves unique MicroReservoirs made from biodegradable polymer intermixed with the anti-restenotic drug sirolimus. These MicroReservoirs provide controlled and sustained release of the drug. Extended release of sirolimus from stents has been proven highly efficacious in both coronary and peripheral vasculatures. MedAlliance’s proprietary CAT™ (Cell Adherent Technology) enables the MicroReservoirs to be coated onto balloons and adhere to the vessel lumen when delivered via an angioplasty balloon.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy